Enovis (NYSE:ENOV) Stock Rating Lowered by Zacks Research

Enovis (NYSE:ENOV) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms also recently issued reports on ENOV. Evercore reissued an “outperform” rating and issued a $36.00 target price on shares of Enovis in a research report on Friday, May 8th. Wells Fargo & Company cut their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. William Blair started coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Finally, Needham & Company LLC increased their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Enovis Price Performance

NYSE ENOV opened at $21.87 on Monday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The stock’s fifty day moving average price is $24.02 and its 200 day moving average price is $24.98. Enovis has a 1 year low of $20.82 and a 1 year high of $36.82. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -1.10 and a beta of 1.38.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same period in the prior year, the firm earned $0.81 EPS. The firm’s revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts forecast that Enovis will post 3.65 earnings per share for the current year.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently modified their holdings of the business. California State Teachers Retirement System grew its position in shares of Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after acquiring an additional 621 shares during the period. MGO One Seven LLC grew its position in shares of Enovis by 9.4% during the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock valued at $202,000 after acquiring an additional 650 shares during the period. Rhumbline Advisers grew its position in shares of Enovis by 0.4% during the 3rd quarter. Rhumbline Advisers now owns 173,023 shares of the company’s stock valued at $5,250,000 after acquiring an additional 682 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. Finally, Empowered Funds LLC grew its position in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after acquiring an additional 749 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.